Bringing the fundamentals into focus…
Back to AngioDynamics, Inc.
How AngioDynamics, Inc. stacks up
ANGO · against 452 other Healthcare companies of similar size
Valuation
29/ 100
Below the middle of the pack.
Ranked #286 of 453 · scores higher than 36% of peers
Bars: peers in each 10-point band of the valuation score6 peers with a valuation score of 20–29, including ANGO · Click a bar to see the companies
Why valuation scores 29?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -6.7% vs peer median 1.5%
- less operating profit (EBITDA) for the company's total value: weaker than 68% of peers. EBITDA yield: 0.0% vs peer median 4.0%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 0.3% vs peer median 0.0%
Metric by metric
Position: dot = ANGO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ANGO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 441 reported | -7.5% | 0.5% | 28% | 30% | |
| EBITDA yieldHigher is better · 458 reported | 0.0% | 3.3% | 38% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | 0.1% | -7.1% | 68% | 20% | |
| Book yieldHigher is better · 450 reported | 34.9% | 48.6% | 35% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ANGOScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score